Milpitas, CA, and Atlanta, GA, February 7, 2019 – Bigfoot Biomedical, Inc., a diabetes company focused on data-driven solutions for insulin dosing and delivery optimization, today announced a commercial supply agreement with Owen Mumford, a worldwide leader in medical device design and manufacturing, to include Owen Mumford’s Unifine Pen Needles within Bigfoot’s upcoming connected injection system subscription bundles.
More than 5 million Americans with insulin-requiring diabetes use injection therapy to manage their condition. However, insulin dosing involves complex guidelines, there are limited tools to track insulin administration, and few robust solutions that enable healthcare providers to support patients following prescribed insulin regimens. Bigfoot’s goal is to offer injection systems as a monthly subscription and integrate insulin dosing support with glucose management, aiming to lower the daily challenges of diabetes management for people who require insulin.
For the pen needles that will be offered through Bigfoot’s auto-fulfillment supply service, the company evaluated several options and selected Owen Mumford’s Pentips Pen Needle line for its compatibility with all disposable insulin pens, availability in popular sizes, comfort, consistent performance, and Owen Mumford’s reputation as a top global pen needle manufacturer.
“Bringing Owen Mumford’s Pentips into our supply bundles ensures our customers always receive a high quality, comfortable pen needle for every insulin dose.” – Jeffrey Brewer, co-founder and CEO
“As a company made up of people living with diabetes, we recognize that getting and managing diabetes supplies is one of the biggest non-therapy burdens for patients,” said Jeffrey Brewer, Bigfoot Biomedical co-founder and CEO. “Including Owen Mumford’s Pentips in our supply bundles will ensure our customers always have access to a high quality, comfortable pen needle for each insulin dose.”
“We’re excited to back Bigfoot’s innovative approach to injection systems by providing our Pentips line,” said Travis Shaw, Executive Vice President at Owen Mumford USA, Inc. “We look forward to building a strong partnership rooted in our shared dedication to quality products for insulin pen users.”
Bigfoot is developing a digital drug delivery platform to support all people with insulin-requiring diabetes, from those just starting injections to patients using advanced infusion pumps. By leveraging user-centered design and smartphone connectivity, Bigfoot’s platform will help people dose insulin accurately and safely, support healthcare providers in achieving better health outcomes, and help payers improve population health while lowering costs. The company expects to commercially launch its first two systems, Bigfoot Inject and Bigfoot Loop, in 2020, pending successful clinical trial completion and regulatory approval.
About Bigfoot Biomedical, Inc
Bigfoot Biomedical was founded by individuals personally connected to type 1 diabetes. With its Loop and Inject systems, the company aims to ease the burden for people requiring insulin and empower healthcare providers through data, connectivity, automation, and artificial intelligence. Learn more at bigfootbiomedical.com. Follow us on Twitter @BigfootBiomed and Facebook.
About Owen Mumford
Owen Mumford has driven medical device innovation for over 60 years, providing solutions that enhance healthcare delivery and home medical treatments worldwide. Their products range from devices that make blood testing easier (Unistik Safety Lancets, Unilet Lancets, Autolet Lancing Devices) to those simplifying administration of vital medications (Autoject Injection Aids, Autopen Cartridge Therapy Devices, Unisafe Safety Syringes, Unifine Pen Needles). Owen Mumford’s legacy in medical devices began in the 1950s with founders Ivan Owen and John Mumford. Through direct sales offices and an international network of distribution partners, Owen Mumford serves customers in over 60 countries and employs more than 800 people across the Americas, Europe, and Asia. Learn more at owenmumford.com.
Media Contacts:
- Melissa Lee, Bigfoot Biomedical mlee@bigfootbiomedical.com, (408) 514-4413
- Casey Pflieger, Owen Mumford casey.pflieger@owenmumford.com, (770) 977-2226
References
1. Seagrove Partners, Diabetes Bluebook 2018